MiR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1133-1142

  McCormick, R I ^a,b   Blick, C ^a   Ragoussis, J ^c   Schoedel, J ^d   Mole, D R ^d   Young, A C ^d   Selby, P J ^e   Banks, R E ^e   Harris, A L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

HIF; hypoxia; miRNA; prognosis; renal cancer; VHL

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; IRON SULFUR PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; MICRORNA 210; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CORTEX; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IRON-SULFUR PROTEINS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MUTATION; PROGNOSIS; UP-REGULATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84875414244     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.56     Document Type: Article

References (38)

1. Biswas S, Roy S, Banerjee J, Hussain SR, Khanna S, Meenakshisundaram G, Kuppusamy P, Friedman A, Sen CK (2010) Hypoxia inducible microRNA210 attenuates keratinocyte proliferation and impairs closure in a murinemodel of ischemic wounds. Proc Natl Acad Sci USA 107: 6976-6981.
2. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS (2003) Carbonic anhydrase IX is an independentpredictor of survival in advanced renal clear cell carcinoma: implicationsfor prognosis and therapy. Clin Cancer Res 9: 802-811.
3. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS (2004) Prognostic valueof carbonic anhydrase IX and KI67 as predictors of survival for renal clearcell carcinoma. J Urol 171: 2461-2466.
4. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J (2008) hsa-miR-210 Is induced by hypoxia and isan independent prognostic factor in breast cancer. Clin Cancer Res 14:1340-1348.
5. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J (2009) MicroRNA-210 controls mitochondrial metabolism during hypoxia byrepressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab10: 273-284.
6. Chen Z, Li Y, Zhang H, Huang P, Luthra R (2010) Hypoxia- regulatedmicroRNA-210 modulates mitochondrial function and decreases ISCUand COX10 expression. Oncogene 29: 4362-4368.
7. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxiaregulatedmarker, carbonic anhydrase IX, in invasive breast carcinoma.J Clin Oncol 19: 3660-3668.
8. Covello KL, Simon MC, Keith B (2005) Targeted replacement of hypoxiainduciblefactor-1alpha by a hypoxia-inducible factor-2alpha knock-inallele promotes tumor growth. Cancer Res 65: 2277-2286.
9. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM (2006) Concordant regulation of gene expression by hypoxia and2-oxoglutarate- dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281: 15215-15226.
10. Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, Devlin C, Blick C, Buffa F, Li JL, Vojnovic B, Pires das Neves R, Glazer P, Iborra F, Ivan M, Ragoussis J, Harris AL (2010) MicroRNA-210 regulatesmitochondrial free radical response to hypoxia and krebs cycle in cancercells by targeting iron sulfur cluster protein ISCU. PLoS One 5: e10345.
11. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S, Zion O, Benjamin S, Benjamin H, Kuker H, Avivi C, Rosenblatt K, Polak-CharconS, Ramon J, Rosenfeld N, Spector Y (2010) Accurate molecularclassification of renal tumors using microRNA expression. J Mol Diagn 12:687-696.
12. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL (2010) hsa-mir-210is a marker of tumor hypoxia and a prognostic factor in head and neckcancer. Cancer 116: 2148-2158.
13. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC (2007) HIF-2alphapromotes hypoxic cell proliferation by enhancing c-myc transcriptionalactivity. Cancer Cell 11: 335-347.
14. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL (2008) HIF-alpha effects on c-Myc distinguish twosubtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell14: 435-446.
15. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. NatRev Cancer 2: 38-47.
16. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM (1994) Silencing of the VHL tumorsuppressorgene by DNA methylation in renal carcinoma. Proc Natl AcadSci USA 91: 9700-9704.
17. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC (2010) Circulating miR-210 as a novel hypoxia marker inpancreatic cancer. Transl Oncol 3: 109-113.
18. Huang WC, Swietach P, Vaughan-Jones RD, Glitsch MD (2009) Differentiation impairs low pH-induced Ca2\+ signaling and ERKphosphorylation in granule precursor tumour cells. Cell Calcium 45:391-399.
19. Iliopoulos O, Kibel A, Gray S, Kaelin Jr WG (1995) Tumour suppressionby the human von Hippel-Lindau gene product. Nat Med 1: 822-826.
20. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G, Liou LS (2010) Identification of a microRNA panel for clearcellkidney cancer. Urology 75: 835-841.
21. Kulshreshtha R, Ferracin M, Negrini M, Calin GA, Davuluri RV, Ivan M (2007) Regulation of microRNA expression: the hypoxic component.Cell Cycle 6: 1426-1431.
22. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD (2002) The contribution of VHL substrate binding and HIF1-alphato the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-255.
23. McCormick R, Buffa FM, Ragoussis J, Harris AL (2010) The role of hypoxiaregulated microRNAs in cancer. Curr Top Microbiol Immunol 345: 47-70.
24. Nakada C, Tsukamoto Y, Matsuura K, Nguyen TL, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M (2011) Overexpression of miR-210, adownstream target of HIF1alpha, causes centrosome amplification in renalcarcinoma cells. J Pathol 224: 280-288.
25. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM (2010) The VHL-dependent regulation of microRNAs in renal cancer. BMC Med8: 64.
26. Pillai RS (2005) MicroRNA function: multiple mechanisms for a tiny. RNARNA 11: 1753-1761.
27. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Yla-Herttuala S (2008) Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 andneuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 582:2397-2401.
28. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2005) Contrasting properties ofhypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel- Lindauassociatedrenal cell carcinoma. Mol Cell Biol 25: 5675-5686.
29. Rouault TA, Tong WH (2008) Iron-sulfur cluster biogenesis and humandisease. Trends Genet 24: 398-407.
30. Saarnio J, Parkkila S, Parkkila AK, Waheed A, Casey MC, Zhou XY, Pastorekova S, Pastorek J, Karttunen T, Haukipuro K, Kairaluoma MI, SlyWS (1998) Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelialcells with the highest proliferative capacity. J Histochem Cytochem 46:497-504.
31. Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, Lichtenfels R (2007) Ubiquitin COOH-terminal hydrolase 1: a biomarkerof renal cell carcinoma associated with enhanced tumor cell proliferationand migration. Clin Cancer Res 13: 27-37.
32. Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G (2011) MicroRNA-210 regulates cancer cell proliferationthrough targeting fibroblast growth factor receptor-like 1 (FGFRL1) . J BiolChem 286: 420-428.
33. Valera VA, Walter BA, Linehan WM, Merino MJ (2011) Regulatory effects ofmicroRNA-92 (miR-92) on VHL gene expression and the hypoxicactivation of miR-210 in clear cell renal cell carcinoma. J Cancer 2:515-526.
34. Weng L, Wu X, Gao H, Mu B, Li X, Wang JH, Guo C, Jin JM, Chen Z, Covarrubias M, Yuan YC, Weiss LM, Wu H (2010) MicroRNA profilingof clear cell renal cell carcinoma by whole-genome small RNA deepsequencing of paired frozen and formalin-fixed, paraffin-embedded tissuespecimens. J Pathol 222: 41-51.
35. White NM, Bao TT, Grigull J, Youssef YM, Girgis A, Diamandis M, Fatoohi E, Metias M, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Yousef GM (2011) miRNA profiling for clear cell renal cell carcinoma: biomarkerdiscovery and identification of potential controls and consequences ofmiRNA dysregulation. J Urol 186: 1077-1083.
36. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE (2009) Analysis of VHL gene alterations and their relationshipto clinical parameters in sporadic conventional renal cell carcinoma. ClinCancer Res 15: 7582-7592.
37. Yuen JS, Cockman ME, Sullivan M, Protheroe A, Turner GD, Roberts IS, Pugh CW, Werner H, Macaulay VM (2007) The VHL tumorsuppressor inhibits expression of the IGF1R and its loss induces IGF1Rupregulation in human clear cell renal carcinoma. Oncogene 26:6499-6508.
38. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER (2002) Identification ofcyclin D1 and other novel targets for the von Hippel-Lindau tumorsuppressor gene by expression array analysis and investigation of cyclinD1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62:3803-3811.